WDR5 is a Prognostic Biomarker of Brain Metastasis from Non-small Cell Lung Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Oct 17

PMID 36249032

Authors

Zheng Li

Nan Liang

Na Wang

Yan Jia

Cui Tian

Affiliations

Soon will be listed here.

Abstract

Background: Lung cancer (LC) is the most frequent caner type and causes the most cancer-related death. Brain metastases (BM) are the deadliest complications of lung cancer, and the prognostic biomarkers of BM are urgently needed.

Materials And Methods: In our study, we established an inception cohort including 122 patients with asynchronous BM from NSCLC, and further selected 70 patients who received surgical resection, which compromised the validation cohort. With immunohistochemistry, we investigated the expression of WDR5 in the cohort. By chi-square method, the correlations between WDR5 and clinicopathological factors were analyzed. The prognostic indicators were analyzed with the univariate analysis, and independent prognostic factors were identified by multivariate analysis with Cox-regression model.

Results: WDR5 is frequently expressed in the cytoplasm of BM from NSCLC. Patients with low or high expression of WDR5 account for 60% and 40% respectively. High expression of WDR5 indicates poor prognosis of BM from NSCLC (=0.001). In addition to WDR5, KPS is also a prognostic factor of BM, and high KPS predicts favorable prognosis (=0.006). WDR5 is an independent prognostic biomarker for poor prognosis of BM from NSCLC, with the cancer-related odds as 2.48.

Conclusions: High expression of WDR5 can predict the poor prognosis of BM, and WDR5 is an independent prognostic biomarker of BM from NSCLC. Patients with WDR5 overexpression are more high-risk to suffer BM-related death and should receive more intense post-operational supervision.

Citing Articles

Exploring the Molecular Tumor Microenvironment and Translational Biomarkers in Brain Metastases of Non-Small-Cell Lung Cancer.

Wen J, Yu J, Liu C, Ould Ismail A, Ma W Int J Mol Sci. 2024; 25(4).

PMID: 38396722 PMC: 10889194. DOI: 10.3390/ijms25042044.

LncRNA AC142119.1 facilitates the progression of neuroblastoma by epigenetically initiating the transcription of MYCN.

Yang R, Liu N, Li T, Liu F, Zhang J, Zhao H J Transl Med. 2023; 21(1):659.

PMID: 37741985 PMC: 10518117. DOI: 10.1186/s12967-023-04535-3.

CCKAR is a biomarker for prognosis and asynchronous brain metastasis of non-small cell lung cancer.

Liang N, Sun S, Li Z, Wu T, Zhang C, Xin T Front Oncol. 2023; 12:1098728.

PMID: 36733361 PMC: 9886659. DOI: 10.3389/fonc.2022.1098728.

A Response to Article Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year after Standard Treatment [Letter].

Panjaitan N Onco Targets Ther. 2022; 15:1405-1406.

PMID: 36444283 PMC: 9700466. DOI: 10.2147/OTT.S396245.

References

Carugo A, Genovese G, Seth S, Nezi L, Rose J, Bossi D . In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Rep. 2016; 16(1):133-147. DOI: 10.1016/j.celrep.2016.05.063. View

Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T . Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37(4):745-51. DOI: 10.1016/s0360-3016(96)00619-0. View

Chen X, Xie W, Gu P, Cai Q, Wang B, Xie Y . Upregulated WDR5 promotes proliferation, self-renewal and chemoresistance in bladder cancer via mediating H3K4 trimethylation. Sci Rep. 2015; 5:8293. PMC: 4319178. DOI: 10.1038/srep08293. View

Bovi J, White J . Radiation therapy in the prevention of brain metastases. Curr Oncol Rep. 2011; 14(1):55-62. DOI: 10.1007/s11912-011-0208-6. View

Succony L, Rassl D, Barker A, McCaughan F, Rintoul R . Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies. Cancer Treat Rev. 2021; 99:102237. DOI: 10.1016/j.ctrv.2021.102237. View

Tan X, Chen S, Wu J, Lin J, Pan C, Ying X . PI3K/AKT-mediated upregulation of WDR5 promotes colorectal cancer metastasis by directly targeting ZNF407. Cell Death Dis. 2017; 8(3):e2686. PMC: 5386518. DOI: 10.1038/cddis.2017.111. View

Goncalves P, Peterson S, Vigneau F, Shore R, Quarshie W, Islam K . Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data. Cancer. 2016; 122(12):1921-7. PMC: 4892979. DOI: 10.1002/cncr.30000. View

Thomas L, Foshage A, Weissmiller A, Tansey W . The MYC-WDR5 Nexus and Cancer. Cancer Res. 2015; 75(19):4012-5. PMC: 4592407. DOI: 10.1158/0008-5472.CAN-15-1216. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

10.

Du K, Wu X, Ji X, Liang N, Li Z . Early growth response 1 promoted the invasion of glioblastoma multiforme by elevating HMGB1. J Neurosurg Sci. 2020; 67(4):422-430. DOI: 10.23736/S0390-5616.20.05107-3. View

11.

Singh Achrol A, Rennert R, Anders C, Soffietti R, Ahluwalia M, Nayak L . Brain metastases. Nat Rev Dis Primers. 2019; 5(1):5. DOI: 10.1038/s41572-018-0055-y. View

12.

Xie Q, Li Z, Chen J . WDR5 positively regulates p53 stability by inhibiting p53 ubiquitination. Biochem Biophys Res Commun. 2017; 487(2):333-338. DOI: 10.1016/j.bbrc.2017.04.060. View

13.

Ji A, Qian L, Tian Z, Cui J . WDR5 promotes the proliferation of lung adenocarcinoma by inducing SOX9 expression. Biomark Med. 2021; 15(17):1599-1609. DOI: 10.2217/bmm-2021-0184. View

14.

Budczies J, von Winterfeld M, Klauschen F, Bockmayr M, Lennerz J, Denkert C . The landscape of metastatic progression patterns across major human cancers. Oncotarget. 2014; 6(1):570-83. PMC: 4381616. DOI: 10.18632/oncotarget.2677. View

15.

Chen T, Li K, Liu Z, Liu J, Wang Y, Sun R . WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1α accumulation in Myc-dependent and independent pathways. Mol Ther. 2021; 29(6):2134-2150. PMC: 8178527. DOI: 10.1016/j.ymthe.2021.02.017. View

16.

Dai X, Guo W, Zhan C, Liu X, Bai Z, Yang Y . WDR5 Expression Is Prognostic of Breast Cancer Outcome. PLoS One. 2015; 10(9):e0124964. PMC: 4565643. DOI: 10.1371/journal.pone.0124964. View

17.

Johung K, Yeh N, Desai N, Williams T, Lautenschlaeger T, Arvold N . Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. J Clin Oncol. 2015; 34(2):123-9. PMC: 5070549. DOI: 10.1200/JCO.2015.62.0138. View

18.

Na I, Lee T, Choe D, Cheon G, Kim C, Koh J . A diagnostic model to detect silent brain metastases in patients with non-small cell lung cancer. Eur J Cancer. 2008; 44(16):2411-7. DOI: 10.1016/j.ejca.2008.07.003. View

19.

Guarnaccia A, Tansey W . Moonlighting with WDR5: A Cellular Multitasker. J Clin Med. 2018; 7(2). PMC: 5852437. DOI: 10.3390/jcm7020021. View

20.

Calo E, Wysocka J . Modification of enhancer chromatin: what, how, and why?. Mol Cell. 2013; 49(5):825-37. PMC: 3857148. DOI: 10.1016/j.molcel.2013.01.038. View